"Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.

e17584Background: Pembrolizumab monotherapy has shown antitumor activity and acceptable safety in patients with mCRPC previously treated with a next-generation hormone agent (NHA) and docetaxel. Pr... Click to show full abstract

Keywords: docetaxel pretreated; pretreated patients; patients metastatic; pembrolizumab docetaxel; study pembrolizumab; phase study

Journal Title: Journal of Clinical Oncology
Year Published: 2020

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended